U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 221 - 230 of 12911 results

Status:
Investigational
Source:
INN:merigolix [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
INN:navepdekinra [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
INN:fudapirine [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
INN:sofnobrutinib [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Status:
Investigational
Source:
NCT00296556: Phase 2 Interventional Terminated Ulcerative Colitis
(2006)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Rivenprost (ONO-4819) is a potent and selective EP4 receptor agonist. This compound can increase bone formation by stimulating osteoblast differentiation and function, possibly by modulating mesenchymal cell differentiation. Rivenprost has also been studied for its potential to prevent bone loss (in osteoporosis) and stabilize bone implants. Combined with risedronate, rivenprost may be an effective treatment for osteoporosis. A phase II study evaluating rivenprost in ulcerative colitis was terminated in 2009.
Status:
Investigational
Source:
INN:monlunabant [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
NCT04580394: Phase 2 Interventional Completed Obstructive Sleep Apnea
(2020)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
INN:aleniglipron [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
INN:xelaglifam [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
INN:mosperafenib [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)